Abstract
Nanomedicines provide distinct clinical advantages over traditional monomolecular therapeutic and diagnostic agents. Supramolecular nanomedicines made from in-situ self-assembling peptides have emerged as a promising strategy in designing and fabricating nanomedicines. In-situ self-assambly (SA) allows the combination of nanomedicines approach with prodrug approach, which exhibited both advantages of these strategies while addressed the problems of both and thus receiving more and more research attention. In this review, we summarized recently designed supramolecular nanomedicines of in-situ SA peptides in the manner of applications and design principles, and the interaction between the materials and biological environments was also discussed.
Highlights
Nanomedicine utilizes nanotechnology to treat or prevent human diseases
2.5 Other Therapy Besides Directly Drug Delivery based on the “in vivo self-assembly” strategy, a polymerpeptide-porphyrin conjugate (PPPC) that could be monitored at the site of infection in real time was developed for precise deep sonodynamic therapy (SDT). (Wang D et al, 2021)
The results showed that for the PPPC group, the concentration calculated based on the T1 value is similar to the concentration calculated based on the T2 value, but for the MnTCPP group, the concentration calculated based on the T1 value and the T2 value was significantly different to calculate the concentration of each group at the target site, which indicated that magnetic resonance imaging (MRI) can accurately quantify MnTCPP in PPPC instead of free MnTCPP (Figure 8D)
Summary
Nanomedicine utilizes nanotechnology to treat or prevent human diseases. Nanomedicine-based drug delivery systems often show enhanced therapeutic efficacy, lower toxicity and improved bioavailability and selectivity than conventional free drugs (Gao et al, 2012; Oberoi et al, 2013) because of their sizes (10–100 nm), large amount of drug loading and targeted surface functionalization. (Xie et al, 2010; Blanco et al, 2015; Lim et al, 2015; Shi et al, 2017; Sato et al, 2018). In-situ self-assembly (SA) of drug-peptide conjugates, which integrated the approaches of nanomedicine and prodrug, have emerged as a promising strategy in targeted delivery of therapeutic agents and diagnostic molecules. 2018), hydrogen peroxide and some other reactive oxygen species, (Miao et al, 2013; Wu et al, 2019), and abnormally expressed enzymes like esterases, proteases and phosphatases, (Li et al, 2015; Shi et al, 2018; Wang H et al, 2019), such in-situ SA approach gained success in enhancing the permeability of nanomedicine and increasing the concentration of therapeutic agents at disease sites. Two main categories of applications are identified and discussed for in-situ SA peptides, namely drug delivery and diagnosis Key concepts such as molecular design, synthetic routes and the interaction between the materials and biological environments will be discussed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
